Cefpirome is a new investigational cephalosporin. We designed a study to determine the pharmacokinetics and tolerance of cefpirome in pediatric patients. A single dose of cefpirome was administered intravenously over 15 min to 18 patients (age, 0.5 to 18 years). The doses were 10 mg/kg of body weight for five patients, 25 mg/kg of body weight for seven patients, and 50 mg/kg of body weight for six patients. Blood samples were collected at 0, 0.25, 0.5, 1, 3, 5, and 8 h after the dose, and cefpirome was measured by a high-performance liquid chromatography method. The maximum concentration in serum ranged from about 53.6 to 454 g/ml after doses of 10 to 50 mg/kg. The total body clearance, apparent volume of distribution, and elimination half-life were 2.15 ؎ 0.70 ml/min/kg, 0.32 ؎ 0.32 liter/kg, and 1.8 ؎ 1.3 h, respectively. No significant adverse effects were attributed to cefpirome. These data may be useful in conducting efficacy and safety studies of cefpirome in pediatric patients.
Cefpirome is a new investigational cephalosporin. In vitro studies have demonstrated its activity against ceftazidime-resistant enterobacteria and methicillin-susceptible Staphylococcus aureus and Staphylococcus epidermidis and offered evidence of some activity against Pseudomonas aeruginosa (2) . In healthy adults, cefpirome provided greater bactericidal activity against S. aureus and Enterobacter cloacae in serum than ceftazidime and ceftriaxone; it was slightly less active against P. aeruginosa than ceftazidime (11) .
The pharmacokinetics of cefpirome have been studied in adults (1, 3, 5-7, 9, 11) . The pharmacokinetics are comparable to those of ceftazidime (11) . Cefpirome penetrates into blister fluid, prostatic tissue, and cerebrospinal fluid (3, 10, 12, 13) . No data are available, however, about its pharmacokinetics in the pediatric population. The purpose of our study was to determine the pharmacokinetics and safety of cefpirome after administration of a single dose in pediatric patients.
(This work was presented at the annual meeting of the American College of Clinical Pharmacy, St. Louis, Mo., 24 August 1994.)
The study was approved by the Human Subjects Research Committee at the Children's Hospital, Columbus, Ohio. Informed consent was obtained from a parent or legal guardian prior to enrollment of each patient. An assent was also obtained from patients older than 12 years of age.
Infants and children between the ages of six months and 18 years who were being hospitalized for the treatment of a systemic infection were eligible for enrollment. The exclusion criteria included any history of allergy or hypersensitivity to any penicillin or cephalosporin for either the patient or the patient's mother, impaired renal or hepatic function, leukopenia, neutropenia or thrombocytopenia, use of an investigational drug within 4 weeks preceding the study, treatment within the previous 3 months with any drug (e.g., chloramphenicol) known to have a well-defined potential for toxicity to a major organ, any history of cystic fibrosis, and pregnancy.
The patients were divided into four age groups (13 to 18 years, 6 to 12 years, 2 to 5 years, and 0.5 to 2 years) and three dose groups (10 mg/kg of body weight, 25 mg/kg of body weight, and 50 mg/kg of body weight). The patients in the 13-to-18-year-old group and 10-mg/kg dose group were studied first, and those in the 0.5-to-2-year-old group and 50-mg/kg dose group were enrolled last. This was done to assure that cefpirome was safe and well tolerated in older patients before younger patients were enrolled and so that smaller doses were used before larger doses.
A single dose of cefpirome was administered intravenously over a 15-min period with a mechanical infusion pump. This dose was used as a replacement dose for cefuroxime, ceftriaxone, or cefotaxime after patients had been treated with one of these drugs for at least 3 days. The decision to administer cefpirome was made only with the consent of the attending physicians of the patients.
Medical history, physical examination, and laboratory tests (complete blood count with differential and platelet count, serum chemistry, urinalysis, and electrocardiogram) were performed prior to drug administration and at 24 h thereafter. If abnormal results were obtained, the tests were repeated and the cause of abnormality was determined.
The blood samples (0.5 ml each) were collected at 0 h (just prior to starting the cefpirome infusion) and at 0.25, 0.5, 1, 3, 5, 8, and 12 h after drug administration. The plasma was separated and stored at Ϫ70ЊC until it was analyzed by a high-performance liquid chromatographic method. The drug was stable during 6 months of storage. The concentrations in the linear range extended from 0.5 to 500 g/ml. The interday and intraday coefficient of variation was less than 6%, and concurrently used drugs did not interfere with the quantitation of cefpirome (8) .
Means and standard deviations were calculated for the observed peak concentrations in plasma (C max ) and other pharmacokinetic parameters. The area under the plasma concentration-time curve was determined by the trapezoidal method and extrapolated to infinity by dividing the last concentration in plasma by the elimination rate constant. The elimination rate constant was calculated by least-squares regression analysis of the terminal portion of the log plasma concentrationtime data. Total clearance (CL) was determined by dividing the dose by the area under the concentration-time curve, the apparent volume of distribution was determined by dividing CL by the elimination rate constant, and the elimination half-life was determined by dividing 0.693 by the elimination rate constant.
Eighteen pediatric patients participated in the study. The cefpirome doses were 10 mg/kg for five patients, 25 mg/kg for seven patients, and 50 mg/kg for six patients. The pharmacokinetic data for cefpirome are presented in Table 1 .
The mean C max s of cefpirome were 153.7 g/ml at doses of 10 mg/kg, 214.3 g/ml at doses of 25 mg/kg, and 437.5 g/ml at doses of 50 mg/kg. The C max was observed at 0.25 h, although it may have occurred at some time between the sampling periods.
The mean CL, apparent volume of distribution, and elimination half-life were 2.15 ml/min/kg, 0.32 liter/kg, and 1.75 h, respectively. The CL of cefpirome in our pediatric patients (2.15 ml/min/kg) was found to be higher than the recently reported value (1.47 ml/min/kg) for healthy adults (11). This was not surprising, because the CL of other cephalosporins in children has been reported to be higher than that in adults (4) .
The relationship between age or dose and pharmacokinetics is difficult to determine because of the small number of patients studied. The reason why mean C max values are proportionately lower at higher doses is unclear.
Our study showed that cefpirome doses of 10 to 50 mg/kg were well tolerated and resulted in C max values exceeding the MIC by several fold. Specific dosage guidelines, however, should await the completion of clinical studies of cefpirome in pediatric patients. 
